Trials / Terminated
TerminatedNCT02646800
Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp
A Multi-center, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 105 (actual)
- Sponsor
- Astellas Pharma China, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the safety and efficacy of intravenous micafungin for the treatment of adult patients in China infected by Candida spp or Aspergillus spp.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Micafungin | Injection |
Timeline
- Start date
- 2014-03-21
- Primary completion
- 2014-12-21
- Completion
- 2014-12-21
- First posted
- 2016-01-06
- Last updated
- 2024-11-07
Locations
16 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02646800. Inclusion in this directory is not an endorsement.